Golden Eagle Partners (3)
A Trusted Advisor to Global Cannabis and Psychopharmacology Companies. Our combined experience in the cannabis, psychopharmacology and life science sectors helps us confidently close strategic and financing transactions that match the near- and long-term goals of our clients. We specialize finding the right transaction – mergers, acquisitions, reverse mergers, equity and debt financings and incremental transactions such as licensing, joint ventures and co-development arrangements – to not only survive but thrive.
E172 - 2 - EV21 - Why Big Brands Are Quietly Exploring Cannabis and Psychedelics - Skunk Works Nature AI with David Traylor
What will it take for cannabis and natural compounds to truly enter the mainstream—from toothpaste to energy drinks? In Part 2 of Trevor and Kirk’s conversation with biotech financier and cannabis strategist David Traylor, they discuss how major corporations might explore integrating cannabinoids like CBN and CBD and other natural products into everyday consumer products. David explains how his Skunk Works Nature AI advisory group connects global companies with world-class experts in pharmacology, biotechnology, and regulatory strategy to develop cannabinoid and other natural product based innovations. From potential sleep-supporting CBN toothpaste, to the role of pharmacogenomics and personalized medicine, this episode explores how science, investment, and product development intersect in the cannabis, psychedelic and natural product sectors. Trevor and Kirk also unpack the broader forces shaping the cannabis industry—stigma, regulatory barriers, banking challenges, and the tension between single-molecule pharmaceutical approaches vs. whole-plant medicine. Could big brands like PepsiCo or Red Bull be the catalyst that finally normalizes cannabinoid ingredients in consumer products? And what role does fear, policy, and economics play in slowing cannabis acceptance? Listen now to learn how cannabis science, biotech innovation, and big-industry investment could reshape the future of medicine, consumer products, and natural compounds.
E172-1 Why Big Brands Are Quietly Exploring Cannabis and Psychedelics - Skunk Works Nature AI with David Traylor
E110 - David Traylor and Golden Eagle Partners
David Traylor has 2 undergrad degrees in Bio-Chemistry and Molecular Biology. He is a former pro lacrosse player. He got involved in BioTech in the 1990's and dealt with the difficulties of getting molecules like erythropoietin to market at scale. From there he got into investment banking. Obviously, with that background, the next step is to do cannabis deals on 6 of the 7 continents! Golden Eagle Partners was the first investment banking firm to jump into cannabis, which they did in 2013. In addition to doing international cannabis deals, David's experience has led him to be involved with financial and cannabis related conferences around the world. In fact, David is the reason our co-host Trevor was at CannMed 23 in Florida. Listen as Trevor and David discuss: What is THC+ and THC-? Where is the cannabis industry going in the next three years? Did Canada blow it on the business side of cannabis when all that money poured in post national legalization in 2018? Why is it so hard to scale a biological product like cannabinoids? David wraps up with talking about the importance of humility when dealing with cannabis. Whether that is dealing with patients, growing the plant or navigating the cannabis business world, we think a reminder to be humble is a wonderful mantra!